Business
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy\n\n\n .bwlistdisc { list-style-type: disc }\n \n\n\n\n\n\n Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated\n \n\n\n\n Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent steroids\n \n\n\n\n Potential trend to improved grip strength observed, with average strength across the study participants doubling from ~2kg to ~4kg\n \n\n\n\n Study participants will have the option to enroll into an 11-month, long-term follow-up study\n \n\n\n\n Satellos plans to advance SAT-3247 into a placebo-controlled Phase 2 trial following additional data analysis and regulatory engagement\n \n\n\n\n\n\n\n\n Satellos Bioscience Inc.\n \n\n\n (TSX: MSCL, OTCQB: MSCLF)\n \n (“\n \n Satellos\n \n ” or the “\n \n Company\n \n ”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced promising Phase 1b data, in an open-label study treating five adult male DMD patients, ages 20 – 27, demonstrating early signs that SAT-3247 may have the potential to affect grip strength, which could represent a clinically meaningful measure for patients with DMD.\n \n\n “We have gained valuable insights from this study of SAT-3247, and we are deeply grateful to the participants,” said Satellos Co-founder and Chief Executive Officer Frank Gleeson. “Given the short 28-day treatment window, the severity and variability of disease in this population, who have limited remaining muscle, we are encouraged by these initial data — particularly, the apparent trend of improved grip strength. Improvements in muscle strength have consistently been an early signal of a possible drug effect in our preclinical studies, where treatment with SAT-3247 led to notable increases in muscle force in both rodent and canine models of DMD. We believe the findings from this Phase 1b study support our plan to advance SAT-3247 into a placebo-controlled Phase 2 trial. We look forward to engaging with regulators and sharing more about our next steps.”\n \n\n SAT-3247 is designed to address progressive muscle ...